[go: up one dir, main page]

WO2024158867A1 - Composition pour le traitement d'affections dermatologiques et son procédé de fabrication - Google Patents

Composition pour le traitement d'affections dermatologiques et son procédé de fabrication Download PDF

Info

Publication number
WO2024158867A1
WO2024158867A1 PCT/US2024/012704 US2024012704W WO2024158867A1 WO 2024158867 A1 WO2024158867 A1 WO 2024158867A1 US 2024012704 W US2024012704 W US 2024012704W WO 2024158867 A1 WO2024158867 A1 WO 2024158867A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
composition
arnica
bromelain
dragon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/012704
Other languages
English (en)
Inventor
Shay SIM
Nadya KOZLOVA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viktor Michael LLC
Original Assignee
Viktor Michael LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viktor Michael LLC filed Critical Viktor Michael LLC
Publication of WO2024158867A1 publication Critical patent/WO2024158867A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • Botanical ingredients have long been used topically for a wide range of cosmetic and therapeutic applications.
  • arnica montana an herb native to the Siberian mountains and Central Europe, has been used for the treatment of pain, stiffness, and swelling associated with trauma, contusions, sprains, myocarditis, cardiac insufficiency, arteriosclerosis, angina pectoris, postoperative clinical conditions, and for symptomatic relief in osteoarthritis.
  • the sesquiterpene lactones of the arnica montana act to reduce inflammation by inhibiting nuclear factor-KB, which controls the transcription of many genes, including cytokines such as IL-1, IL-2, IL-6, IL-8, and tumor necrosis factor a (TNF-a).
  • cytokines such as IL-1, IL-2, IL-6, IL-8, and tumor necrosis factor a (TNF-a).
  • bromelain is another ingredient that has been used to treat inflammatory ailments, such as swelling associated with trauma and contusions.
  • Topical arnica compositions and topical bromelain compositions e.g., such as creams and ointments
  • NCIH National Center for Complementary and Integrative Medicine
  • dragon’s blood Another ingredient that has been used to improve wound healing and treat inflammatory ailments is dragon’s blood.
  • the topical application of dragon’s blood has been associated with a significant improvement of wound healing which may be due to a shortening of the inflammation process because of the presence of phenolic compounds such as proanthocyanidins and catechin.
  • a dragon’s blood composition comprising an emulsion with a 15% ethanolic extract of C. lechleri in an emulsion carrier is known; however, the amount of C. lechleri on an “actives” basis present in the composition is unknown.
  • Wound healing is a complex process.
  • epithelia execute a coordinated program that closes the wound, combats infection, reestablishes barrier function, and restores tissue architecture.
  • MMPs Matrix metalloproteinases
  • Inflammation is a complex process that comprises detection and response to insult and repair of tissues (e.g., leukocyte recruitment).
  • the activity of many of the effector proteins that regulate and coordinate the inflammatory response is, in turn, controlled by proteinases, including MMPs.
  • MMPs The expression of MMPs is upregulated at transcriptional level by numerous inflammatory cytokines including tumor necrosis factor-u. (TNF-a), and by growth factors, including epidermal growth factor (EGF) and transforming growth factor- (TGF- ). Once activated, the activity of MMPs is regulated by general and specific inhibitors, including the family of tissue inhibitors of metalloproteinases (TIMP-1, -2, -3, and -4).
  • TNF-a tumor necrosis factor-u.
  • EGF- epidermal growth factor
  • TGF- transforming growth factor-
  • MMPs regulate recruitment and influx of inflammatory cells to the site of inflammation by acting on a variety of protein substrates, including extracellular matrix proteins (e.g., collagen and elastin), adhesion proteins, cytokines, and chemokines.
  • extracellular matrix proteins e.g., collagen and elastin
  • adhesion proteins e.g., IL-12, IL-12, and IL-12.
  • cytokines cytokines
  • chemokines chemokines
  • MMPs The action of MMPs in inflammation is both direct and indirect. Many chemokines are directly cleaved by MMPs, thereby resulting in enhancement, inactivation or antagonism of chemokine activities. Other chemokines are regulated by MMP cleavage of substrates that bind, retain and concentrate the chemotactic molecules. By establishing chemokine gradients, MMPs help coordinate an influx of immune effector cells, including neutrophils, monocytes and eosinophils.
  • Glycosaminoglycans are unbranched polysaccharides containing a repeating disaccharide unit - specifically, two modified sugars, N-acetylgalactosamine (GalNAc) or N- acetylglucosamine (GlcNAc), and an uronic acid such as glucuronate or iduronate.
  • GAGs are covalently linked to proteins, forming proteoglycans.
  • Two particularly important GAGs are hyaluronic acid and dermatan sulfate.
  • Hyaluronic acid also known as hyaluronan, is a polysaccharide comprised of D-glucuronic acid and N-acetylglucosamine residues. Unlike other GAGs, hyaluronan does not contain sulfate and is not found covalently attached to proteins (i.e., as a proteoglycan).
  • Chronological and environmental skin aging are associated with increased levels of MMPs and other enzymes that degrade not only extracellular matrix proteins (collagen and elastin) but also GAGs.
  • Clinically aging skin is less supple, less elastic, thinner, and more prone to wrinkling.
  • IL-1 interleukin 1
  • IL-6 interleukin 6
  • IL-8 chemokines
  • NF-KB pro-inflammatory transcription factors
  • Oxygen radical absorbance capacity is a method of measuring antioxidant capacity of a sample.
  • Total ORACFN provides a measure of “total antioxidant power” - the ability to quench and reduce levels of these five reactive oxygen species (“ROS”).
  • ROS reactive oxygen species
  • SOD superoxide dismutases
  • one object of the present invention is to provide a composition for treating dermatologic conditions that can reduce inflammation and/or degradation of the cellular matrix.
  • Another object of the present invention is to provide a composition for topical or oral administration that can quench ROS but also promote wound healing.
  • Yet another object of the present invention is to provide a composition that can reduce the visible signs of skin aging.
  • a further object of the present invention is to provide a method for producing such compositions.
  • a topical composition comprising: an anti-inflammatory, anti-edema, anti-erythema complex (AAA Complex) consisting essentially of (i) bromelain, (ii) Arnica montana and (iii)) Croton lechleri, or another species in the genus Croton and a skin-compatible carrier;
  • AAA Complex anti-inflammatory, anti-edema, anti-erythema complex
  • compositions for treating dermatologic conditions comprising: from 0.1% to 8% babassu oil extract by weight percent; from 1% to 20% arnica oil extract by weight percent; from 0.005% to 1% bromelain extract by weight percent; and from 1% to 9% dragon’s blood extract by weight percent, wherein the composition provides an anti-inflammatory, anti-edema, anti-erythema complex (AAA Complex), and a method for producing such a composition.
  • AAA Complex anti-inflammatory, anti-edema, anti-erythema complex
  • FIGURE l is a flow diagram illustrating an example embodiment of an exemplary method of making a cosmetic composition comprising the active ingredients babassu oil extract, arnica oil extract, bromelain extract, and dragon’s blood extract in accordance with this disclosure.
  • compositions As used in the specification and in the claims, the terms “comprise(s),” “include(s),” “having,” “has,” “can,” “contain(s),” and variants thereof, as used herein, are intended to be open- ended transitional phrases, terms, or words that require the presence of the named ingredients/steps and permit the presence of other ingredients/steps.
  • description should be construed as also describing compositions or processes as “consisting of' and “consisting essentially of the enumerated ingredients/steps, which allows the presence of only the named ingredients/steps, along with any unavoidable impurities that might result therefrom, and excludes other ingredients/steps.
  • compositions comprising bromelain extract, arnica extract, dragon’s blood extract, and babassu oil extract in varying amounts by weight percent (%wt/wt) and their methods of manufacture.
  • the bromelain extract, arnica extract, dragon’s blood extract, and babassu oil extract are each active ingredients in the composition.
  • compositions provided herein can be administered to a patient before and/or after the patient undergoes aesthetic medical treatments, such as cosmetic injections (e.g., botox, fillers, etc ), as part of a pre- and postrecovery care routine.
  • cosmetic injections e.g., botox, fillers, etc
  • the compositions disclosed herein can be included in topical and orally-administered products to treat dermatologic conditions, including reducing the appearance of visible signs of skin aging.
  • compositions comprise babassu oil extract, arnica oil extract, bromelain extract, and dragon’s blood extract in the prescribed amounts described below to reduce ecchymosis (bruising) inflammation, swelling (edema), and redness (erythema) by topical and/or oral administration of the composition provided herein.
  • composition comprising the active ingredients babassu oil extract, arnica oil extract, bromelain extract, and dragon’s blood extract contains an anti-inflammatory, anti-edema, anti-erythema complex (AAA Complex) formed from (i) bromelain, (ii) croton lechleri (dragon’s blood) or another species in the genus croton, (iii) arnica montana flower extract, and (iv) orbignya oleifera seed oil (babassu oil).
  • AAA Complex anti-inflammatory, anti-edema, anti-erythema complex
  • Another aspect of the present disclosure is directed to methods and compositions comprising the AAA Complex for reducing the visible signs of skin aging.
  • the AAA Complex possesses the ability to (i) reduce the expression of mRNA coding for (a) at least one MMP and (b) at least one inflammatory cytokine, chemokine and/or pro-inflammatory transcription factor.
  • the AAA Complex reduces the level of expression of genes coded by the above-mentioned proteins by at least about 30%, where the level of gene expression is measured by DNA microarray analysis using a full-thickness epidermal skin tissue model.
  • Ecchymosis is a small hemorrhagic spot in or on the skin or a mucous membrane, forming a non-elevated, rounded or irregular, blue or purplish patch.
  • An ecchymosis is a superficial injury produced by impact without laceration, which results in blood leaking into the surrounding tissue.
  • ecchymosis is to be understood as synonymous with bruising.
  • Bruising is often accompanied by one or more of swelling, edema or an effusion, each as defined below.
  • Swelling is a transient enlargement or increase in volume of a body part or area caused by accumulation of fluid. As used in the present application, swelling is not caused by proliferation of cells.
  • Edema is the presence of increased amounts of fluid (i.e., above homeostatic levels) in the intercellular tissue spaces of the body.
  • An “effusion” is fluid, cells, or cellular debris from blood vessels that deposits in or on the tissues, usually due to inflammation.
  • “Aesthetic medical treatment” means a procedure performed by a physician, an allied health professional (e.g., nurse) or licensed aesthetician for reducing the appearance of one or more signs of skin aging by (a) injecting a dermal filler or botulinum toxin, (b) manual, chemical or instrumental exfoliation of the skin surface (e.g., microdermabrasion, chemical peel, laser peel), (c) laser and intense pulse light skin treatment, (d) microneedling, or (e) liposuction.
  • a “topical product” is a composition, solution, dispersion, emulsion (e.g., oil-in-water or water-in-oil), or suspension, in the form of a cream, lotion, ointment, gel, serum, foam, concealer, mask, mousse, or spray comprising (i) active amounts, by weight percent (%wt/wt), of the babassu oil extract, arnica oil extract, bromelain extract, and dragon’s blood extract, wherein the composition contains the AAA Complex, and (ii) a skin-compatible carrier, as defined below, made according to methodologies well-known in the art, including those found, for example, in the current version of Remington, The Science and Practice of Pharmacy, using cosmetic and/or pharmaceutical ingredients known to the person having ordinary skill in the dermatological and pharmaceutical arts.
  • a “skin-compatible carrier” is a chemical composition which when applied to the skin, hair or nails does not produce irritation, drying or other undesirable sensory properties (e.g., tackiness).
  • the carrier can be in a wide variety, including single-phase, two-phase and multiphase systems.
  • Non-limiting examples of single-phase systems include thickened aqueous dispersions (that do not contain oils, esters, or silicones) as well as anhydrous serums or gels (that do contain water).
  • Two-phase and multi-phase systems both comprised of an internal discontinuous phase which is homogenously dispersed in a continuous external phase - include oil-in-water emulsions, water-in-oil emulsions, water-in-silicone emulsions, silicone-in-water emulsions, as well as water-in-oil-in-water emulsions, oil-in-water-in-oil emulsions, and oil-in-water-in- silicone emulsions.
  • Emulsions contain one or more surfactants which may be anionic, cationic, amphoteric, zwitterionic and non-ionic.
  • An “orally-administered product” is a solid, semi-solid, or liquid dosage form comprised of (i) a composition comprising active amounts, by weight percent (%wt/wt), of babassu oil extract, arnica oil extract, bromelain extract, and dragon’s blood extract, wherein the composition contains the AAA Complex, and (ii) pharmaceutically acceptable excipients, carriers, diluents or additives well-known to those of skill in the art. Orally-administered products may be swallowed, chewed or dissolved (on or under the tongue).
  • Solid dosage forms for oral administration include tablets, pills, soft elastic and hard gelatin capsules, caplets and powders.
  • Liquid dosage forms for oral administration of the compounds include emulsions, micro-emulsions, solutions, suspensions, syrups, and elixirs.
  • Orally-administered dosage forms also include gelatine-based chewables, commonly-known as “gummies”.
  • An “active ingredient” is any ingredient that provides biologically active (pharmacological activity) or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or any function of the body of humans or animals.
  • An “extract” is a substance made by extracting a part of a raw material, often by using a solvent such as ethanol, oil, or water. Most natural essences may be obtained by extracting the essential oil from the feedstock, such as blossoms, fruit, seeds/kemels, and roots, or from intact plants using various extraction techniques and methods. Non-limiting examples of extracts in accordance with this disclosure include tinctures, infusions, and absolutes among others. The extracts may be provided in liquid form or powder form.
  • Numerical ranges are meant to include numbers within the recited range, and combinations of subranges between, the given ranges. For example, a range from 1-5, includes 1, 2, 3, 4 and 5, as well as subranges such as 2-5, 3-5, 2-3, 2-4, 1-4, etc.
  • At least one means one or more, and also includes individual components as well as mixtures/combinations.
  • a composition comprising bromelain extract, arnica extract, dragon’s blood extract, and babassu oil extract.
  • the bromelain extract, arnica extract, dragon’s blood extract, and babassu oil extract are each active ingredients in the composition.
  • the amount (%wt/wt) of each of the active ingredients bromelain extract, arnica extract, dragon’s blood extract, and babassu oil extract in the composition may vary depending on the particular use of the composition.
  • the composition may comprise different amounts of bromelain extract, arnica extract, dragon’s blood extract, and/or babassu oil extract (%wt/wt) depending on whether the composition is being used as a facial serum, lip serum, mask, or concealer.
  • compositions disclosed herein comprise specific amounts (or ranges) of bromelain extract, arnica extract, dragon’s blood extract, and babassu oil extract by weight percent in order to achieve a particular viscosity for the end product which may be affected by whether the resulting composition is prepared for administration in a base such as water or oil.
  • a base such as water or oil.
  • specific amounts (or ranges) of bromelain extract, arnica extract, dragon’s blood extract, and babassu oil extract by weight percent allow for control over properties/characteristics of the composition such as, but not limited to, the smell, oily appearance, residue, and stability in the base (e.g., oil or water).
  • bromelain extract may provide a composition that prioritizes one of anti-inflammatory, anti-edema, or anti-erythema treatment over the others.
  • the composition may further comprise one or more additives.
  • the additives generally comprise cosmetic ingredients that are biologically inactive (pharmacologically inactive). Inactive ingredients provide support for the active ingredient or lend cosmetic benefits like hydration. Non-limiting examples of inactive ingredients include stabilizers, solvents, antioxidants, preservatives, dyes, exfoliants, binding materials, and lipids amongst other functions.
  • the composition may comprise the active ingredients bromelain extract, arnica extract, dragon’s blood extract and babassu oil extract, and may optionally include one or more additives such as titanium dioxide and/or propanediol.
  • the composition comprises an active amount of bromelain extract.
  • the composition may comprise from about 0.005% to about 1% bromelain extract by weight percent (%wt/wt). In other embodiments, the composition may comprise from about 0.008% to about 0.8% bromelain extract by weight percent (%wt/wt). In still other embodiments, the composition may comprise from about 0.01% to about 0.7% bromelain extract by weight percent (%wt/wt). In yet other embodiments, the composition may comprise from about 0.05% to about 0.6% bromelain extract by weight percent (%wt/wt). In still other embodiments, the composition may comprise from about 0.1% to about 0.5% bromelain extract by weight percent (%wt/wt).
  • the active amount of bromelain in the bromelain extract by weight percent (%wt/wt) can vary depending on the particular use of the bromelain extract.
  • the bromelain extract comprises bromelain and one or more additional ingredients, or additives.
  • the bromelain extract may comprise a composition of bromelain and glucose.
  • Bromelain is the active ingredient in the bromelain extract. It is to be appreciated that bromelain is a mixture of enzymes (phosphatases, glucosidases, peroxidases, cellulases) and proteinase inhibitors (specifically, cysteine proteinases).
  • Bromelain is further comprised of glycoproteins and carbohydrates.
  • proteinase inhibitors is bromelain inhibitor VI, an 11 -residue light chain and a 41 -residue heavy chain cross-linked by five inter/intra-chain disulfide bonds.
  • bromelain The enzymatic activity of bromelain is determined with different substrates, including casein [based on standardized units published by International Pharmaceutical Federation (FTP) or the United States Pharmacopeia (USP)], gelatine (gelatine digestion units, or GDUs) or chromogenic tripeptides.
  • casein based on standardized units published by International Pharmaceutical Federation (FTP) or the United States Pharmacopeia (USP)
  • gelatine gelatine digestion units, or GDUs
  • chromogenic tripeptides chromogenic tripeptides.
  • the bromelain extract may be provided in a powder form or a liquid form, such as oil.
  • the bromelain extract is combined with the other active ingredients to form the composition.
  • a bromelain extract is supplied under trade name ARG-BML (available from Argan Co.) and comprises a powder that contains the cosmetic ingredients bromelain and glucose in prescribed ratios.
  • a bromelain extract is supplied as a powder under the tradename SpecPure® BML60 (available from Spec-Chem Industry, Inc.) and comprises at least 55% bromelain by weight percent (%wt/wt) and no more than 45% glucose by weight percent (%wt/wt).
  • a bromelain extract is supplied as a powder under the tradename SpecPure® BML10 (available from Spec- Chem Industry, Inc.) and comprises at least 30% bromelain by weight percent (%wt/wt) and no more than 70% glucose by weight percent (%wt/wt).
  • SpecPure® BML60 and SpecPure® BML10 can be used for whitening/lightening, as an exfoliator to break down and peel aging cells, as an anti-inflammatory helping to reduce redness, bruising and pain, and moisturizing in cosmetics.
  • SpecPure® BML60 and SpecPure® BML10 can be used for treating scar tissue to decompose necrotic tissue and avoid damaging the skin’s healthy living tissue.
  • the bromelain extract may act on the aging stratum comeum of human skin to promote its degradation, decomposition and removal, to promote skin metabolism, to reduce skin dullness caused by sunlight, and to keep skin white. Further, hydrolysate of bromelain can also form a film of amino acid derivative on the skin, keeping the skin moist for a long time and thereby promoting the skin’s absorption of other functional substances.
  • the composition further comprises an active amount of arnica extract.
  • the composition may comprise from about 1% to about 20% arnica extract by weight percent (%wt/wt). In other embodiments, the composition may comprise from about 3% to about 17 % arnica extract by weight percent (%wt/wt). In still other embodiments, the composition may comprise from about 5% to about 15% arnica extract by weight percent (%wt/wt). In yet other embodiments, the composition may comprise from about 5.5% to about 14.5% arnica extract by weight percent (%wt/wt). In still other embodiments, the composition may comprise from about 7% to about 12% arnica extract by weight percent (%wt/wt).
  • the active amount of arnica montana flower extract in the arnica extract by weight percent (%wt/wt) can vary depending on the particular use of the arnica extract.
  • the arnica extract is a mixture suitable for use in cosmetic formulations and personal care products.
  • the arnica extract is a mixture comprising arnica montana flower extract and one or more additional ingredients, or additives.
  • the arnica montana flower extract is the active ingredient in the arnica extract and is comprised of sesquiterpene lactones - in particular, helanalin, 1 loc
  • Non-limiting examples of additives that may be included in the arnica extract include, but are not limited to, extracting agents, stabilizers, and solvents, amongst other ingredients.
  • the arnica extract may be plant-derived and comprise a fatty oil extract formed from arnica blossoms (e.g., arnica montana flower extract).
  • the arnica extract may be soluble in fats and oils.
  • the arnica extract may be provided in a powder form, a liquid form, such as oil, or a combination thereof.
  • the arnica extract may be a mixture comprising arnica montana flower extract, glycine soja (soybean) oil, and tocopherol.
  • the soybean oil may be used as an extracting agent (i.e., is a fatty oil extract) and the tocopherol may be used as a stabilizing additive and antioxidant.
  • a plant-derived arnica extract is supplied under the trade name Arnica Oil CLR (available from Chemisches Laboratorium Dr.
  • Arnica Oil CLR contains the lipid- soluble constituents of arnica blossoms in a vegetable oil medium. It is to be appreciated that Arnica Oil CLR, as an herbal extract based on soybean oil, is non-toxic and easily biodegradable.
  • the arnica extract may be a mixture comprising arnica montana flower extract, helianthus annuus (sunflower) seed oil, and tocopherol.
  • the sunflower seed oil may be used as an extracting agent (i.e., is a fatty oil extract) and the tocopherol may be used as a stabilizing additive and antioxidant.
  • arnica extract is supplied under the trade name GLB Arnica 10 LIPO (available from Green Line Botanicals) and comprises an oil (i.e., liquid) that contains the following cosmetic ingredients: arnica montana flower extract, helianthus annuus (sunflower) seed oil, and tocopherol. It is to be appreciated that this arnica extract is high in sesquiteroene lactones and carotenoids such that the arnica extract is a highly revered skin healer that provides powerful antiseptic, anti-inflammatory, and pain reliever properties.
  • the arnica extract may be a mixture comprising arnica montana flower extract and glycerin.
  • arnica extract is supplied under the trade name GLB Arnica Extract GL (available from Green Line Botanicals) and comprises an oil (i.e., liquid) that contains the cosmetic ingredients arnica montana flower extract and glycerin.
  • One exemplary recommended use is emulsified and oily skin and hair care preparations for preventive care of skin of all types and to promote circulation in skin and scalps poorly supplied with blood. It is to be appreciated that herbal cosmetics containing an arnica extract from arnica blossoms can have a favorable effect on the blow flow in peripheral vessels, an anti-inflammatory effect, and also a granulating and epithelizing effect on tissue.
  • the composition further comprises an active amount of dragon’s blood extract, also referred to as dragon’s blood.
  • the composition may comprise from about 1% to about 9% dragon’s blood extract by weight percent (%wt/wt). In other embodiments, the composition may comprise from about 2% to about 8% dragon’s blood extract by weight percent (%wt/wt). In still other embodiments, the composition may comprise from about 3% to about 7% dragon’s blood extract by weight percent (%wt/wt). In yet other embodiments, the composition may comprise from about 4% to about 6% dragon’s blood extract by weight percent (%wt/wt).
  • the composition may comprise from about 4.5% to about 5.5% dragon’s blood extract by weight percent (%wt/wt).
  • dragon’s blood extract by weight percent (%wt/wt).
  • the amount of croton lechleri resin powder or croton lechleri resin extract in the dragon’s blood extract by weight percent (%wt/wt) can vary depending on the particular application of the dragon’s blood extract and/or cosmetic composition/formulation.
  • dragon’s blood extract is a mixture suitable for use in cosmetic formulations and personal care products.
  • the dragon’s blood extract comprises a composition of croton lechleri resin powder/extract and one or more additional ingredients, or additives.
  • the AAA Complex may include another species in the genus Croton, including, for example, C. draconoides or C. urucnrana.
  • the active ingredient in the dragon’s blood extract may be any one of croton lechleri resin powder, croton lechleri resin extract, or another species in the genus croton.
  • dragon’s blood is a hydro-glycolic extract obtained from the latex of the tree croton lechleri and possesses multiple beneficial properties for skin care treatment.
  • the dragon’s blood extract may be a hydrosoluble composition comprising croton lechleri resin powder, water (aqua), and propanediol that is supplied under the trade name Dragon’s Blood (available from MMP, Inc.).
  • Dragon’s Blood by MMP, Inc. is a hydro-glycolic extract obtained from the latex of the tree croton lechleri and includes, as main components, proanthocyanidins (e.g., polyphenols), taspine, lignans, pigments, and flavonoids.
  • the dragon’s blood extract may be a liposoluble composition comprising croton lechleri resin powder/extract, butyrospermum parkii (shea) butter extract, and argania spinosa kernel oil that is sold under the trade name Dragon’s Blood LP (available from MMP, Inc.).
  • Dragon’s Blood LP by MMP, Inc. is an intensive nutrient butter blend combining exceptional ingredients, like shea butter and argan oil, with an extract obtained from the latex of the tree croton lechleri, with multiple beneficial properties for skin and lip care.
  • the dragon’s blood extract may be hydrosoluble or liposoluble.
  • Dragon’s blood extract may comprise a mixture adapted for use in cosmetics and personal care products to provide for anti-aging and repair, improvement of skin protection, strong anti-free radical activity (ORS and NRS), cicatrizing action, anti-inflammatory activity, moisturizing activity, enhanced skin elasticity, and epigenetic activity.
  • dragon’s blood extract is a natural epigenetic ingredient capable of modulating the expression of microRNAs and genes which control cellular aging.
  • dragon’s blood extract also has the properties of a cicatrizant, due to its high taspine and polyphenols content, stimulating the formation of scabs regenerating the skin faster, and stimulating the production of collagen and the fibroblasts migration.
  • Dragon’s blood extract may have anti -pollution properties by stimulating the synthesis of antioxidant defense genes (e.g., GPX2 (glutathione peroxidase 2), ALDH3B1, AKR1C2) that are involved in the detoxification of hydrocarbons.
  • GPX2 glutathione peroxidase 2
  • ALDH3B1, AKR1C2 antioxidant defense genes
  • Dragon’s blood extract is a natural moisturizer and stimulates the synthesis of aquaporin 3.
  • Dragon’s blood extract has immunostimulator properties evidenced by improving the skin’s barrier function by stimulating the synthesis of tight-junctions, key proteins in the conservation of the skin’s natural immunity.
  • the dragon’ s blood extract included in the composition is comprised of proanthocyanidins, which may have a concentration of greater than about 90%.
  • the proanthocyanidins are oligomers, having a mean degree of polymerization of 4,5-6 and 6-7; but, can be oligomers of up to 20 flavan-3-ol units, with gallocatechin and epigallocatechin being most prevalent.
  • Also present in dragon’s blood extract is the alkaloid taspine.
  • Dragon’s blood extract is available from numerous suppliers of raw materials to of cosmetic and dermatologic products: Naturex (Avumble, France) in powder form (in combination with maltodextrin) or in solution (with glycerol or propylene glycol); MMP, Inc. (South Plainfield, NJ) in solution (resin in propanediol and water); Croda, Inc. (Chanac, France) in solution (resin in glycerine and water); 3QP (Lima, Peru) in solution (sap extract in propanediol and water).
  • the composition further comprises an active amount of babassu oil extract, also known by its INCL name orbignya oleifera kernel oil.
  • the composition may comprise from about 0.1% to about 8% babassu oil extract by weight percent (%wt/wt). In other embodiments, the composition may comprise from about 0.5% to about 6% babassu oil extract by weight percent (%wt/wt). In still other embodiments, the composition may comprise from about 1% to about 5% babassu oil extract by weight percent (%wt/wt). In yet other embodiments, the composition may comprise from about 1.5% to about 4.5% babassu oil extract by weight percent (%wt/wt).
  • the composition may comprise from about 2% to about 4% babassu oil extract by weight percent (%wt/wt). It is to be appreciated that the amount of babassu oil extract in the composition by weight percent (%wt/wt) can vary depending on the particular use of the composition.
  • babassu oil extract may be used as a raw material in cosmetic formulations and personal care products. It is to be appreciated that babassu oil can be used in a variety of cosmetic applications as an active principle or as a carrier in the oily phase and can be an effective emollient (i.e., moisturizer). In some non-limiting examples, babassu oil is suited for use in anti-aging anti-inflammatory products, skin care products such as body milks, creams, lip balms, bath products, and hair care products.
  • Babassu oil extract may be obtained from the babassu palm tree (e.g., attalea martiana, attalea oleifera, or attalea speciosa), also known as the plant orbignya oleifera.
  • Babassu oil comprises a vegetable oil extracted from the kernels of the babassu palm tree.
  • the babassu oil may be obtained by the hydraulic cold pressing of the kernels of the fruits of the babassu palm tree, followed by the subsequent refining, bleaching, and deodorization of the babassu oil.
  • Babassu oil extract is composed of fatty acids and is water insoluble. As such, the babassu oil extract may have the appearance of a semi-solid fat.
  • babassu oil is composed of 70% fatty acids with a smooth solid texture that liquefies once it makes contact with skin.
  • the babassu oil extract comprises orbignya oleifera seed/kemel oil.
  • the babassu oil is physically extracted and subsequently refined, which includes deodorization.
  • a plant-derived babassu oil extract is supplied under trade name IntegriLIPID Babassu Oil (available from Integrity Ingredients Corp.).
  • IntegriLIPID Babassu Oil has the appearance of a semi-solid fat and contains the following fatty acid composition, referred to by INCL naming: caproic, caprylic, lauric, myristic, pamitic, stearic, oleic, linoleic, and total saturated, monounsaturated, and polyunsaturated. It is to be appreciated that variations in fatty acid composition may be due to climatic influences. IntegriLIPID Babassu Oil is non-toxic and easily biodegradable.
  • the composition may further comprise one or more additives.
  • the additives may generally comprise cosmetic ingredients, which are identified in this disclosure according to their International Nomenclature Cosmetic Ingredient (INCI) name.
  • the additives may be selected from the group comprising water (aqua); propanediol; kaolin; olive oil glycereth-8 esters; glycine soja (soybean) oil; glycerin; titanium dioxide; ammonium acryloyldimethyltaurate/VP copolymer; indigofera tinctoria extract; citrullus lanatus (watermelon) fruit extract; lens esculenta (lentil) fruit extract; pyrus malus (apple) fruit extract; zingiber officinale (ginger) root extract; sodium hyaluronate crosspolymer; bisabolol; isopulegol; sodium lactate; sodium PCA; sodium phytate; piperonyl glucose; glucose; mica; tin oxide; chlorphenesin; cap
  • the one or more additives are combined with the active ingredients - for example, bromelain extract, arnica extract, dragon’s blood extract, and babassu oil extract - to form compositions that are configured to be used for masks, facial serums, lip serums, and/or concealers.
  • active ingredients for example, bromelain extract, arnica extract, dragon’s blood extract, and babassu oil extract - to form compositions that are configured to be used for masks, facial serums, lip serums, and/or concealers.
  • one or more additives may be included in a composition for combination with the active ingredients of the cosmetic composition.
  • additives and additive compositions that may be combined with one or more active ingredients of the cosmetic composition include, but are not limited to, one or more of the following: (i) deionized water (aqua); (ii) a composition comprising sodium phytate and water (aqua) such as that available from Glenn under the trade name demofeel PA-12; (iii) a composition comprising propanediol such as that available from DuPont under the trade name Zemea; (iv) a composition comprising ammonium acryloyldimethyltaurate/VP copolymer such as that available from Clariant under the trade name Aristoflex AVC-USA; (v) a composition comprising olive oil glycereth-8 esters such as that available from Coast Southwest under the trade name olivatis 15; (vi) a composition comprising phenoxyethanol, caprylyl glycol,
  • compositions comprising isopulegol such as that available from Vantage under the trade name Coolact P;
  • a composition comprising isododecane and dimethicone/bis-isobutyl PPG-20 crosspolymer such as that available from Dow Corning under the trade name Dow Corning EL-8050 ID Silicone Organic Blend;
  • a composition comprising caprylic/capric triglyceride such as that available from Argan under the trade name ARG-CCTG;
  • a composition comprising dicaprylyl carbonate and tocopherol such as that available from BASF under the trade name Cetiol CC/MB;
  • a composition comprising fragrance (parfum) such as that available from Harris under the trade name Frag.
  • Table 1 Exemplary Compositions of the Present Invention Comprising Babassu Oil Extract; Arnica Oil Extract; Bromelain Extract; and Dragon’s Blood Extract (%wt/wt). [0084] Examples
  • Table 1 above includes exemplary compositions comprising varying amounts of babassu oil extract, arnica oil extract, bromelain extract, and dragon’s blood extract by weight percent (%wt/wt), in accordance with this disclosure.
  • the compositions disclosed herein may be used as to form cosmetic products and personal care products, such as facial serums, lip serums, concealers, and/or masks.
  • compositions generally comprise, by weight percent (%wt/wt), from about 0.1% to about 8% babassu oil extract, from about 1% to about 20% arnica oil extract, from about 0.005% to about 1% bromelain extract, and from about 1% to about 9% dragon’s blood extract.
  • the compositions may further include one or more additives, which generally are inactive cosmetic ingredients that may act as stabilizers, solvents, antioxidants, preservatives, dyes, exfoliants, binding materials, and lipids amongst other functions.
  • the composition may comprise from about 0.5% to about 6% babassu oil extract, from about 5% to about 15% arnica oil extract, from about 0.008% to about 0.8% bromelain extract, and from about 3% to about 7% dragon’s blood extract by weight percent (%wt/wt) and may be used to form a mask.
  • the composition may further comprise one or more additives.
  • the composition may consist of a viscous cream and, in some instances, the cream may be opaque.
  • the composition comprises about 1% babassu oil extract, about 6% arnica oil extract, about 0.1% bromelain extract, and about 5% dragon’s blood extract by weight percent (%wt/wt) and forms a mask.
  • the composition may comprise from about 0.5% to about 6% babassu oil extract, from about 3% to about 17% arnica oil extract, from about 0.05% to about 0.6% bromelain extract, and from about 3% to about 7% dragon’s blood extract by weight percent (%wt/wt) and may be used to form a serum.
  • the composition may further comprise one or more additives.
  • the serum composition may consist of a semi-viscous liquid and, in some instances, the semi-viscous liquid may be opaque.
  • the composition comprises about 1% babassu oil extract, about 15% arnica oil extract, about 0.1% bromelain extract, and about 5% dragon’s blood extract by weight percent (%wt/wt) and forms a serum and, in particular, a facial serum.
  • the composition comprises about 5% babassu oil extract, about 10% arnica oil extract, about 0.1% bromelain extract, and about 5% dragon’s blood extract by weight percent (%wt/wt) and forms a serum and, in particular, a lip serum.
  • the composition may comprise from about 0.5% to about 6% babassu oil extract, from about 3% to about 17% arnica oil extract, from about 0.01% to about 0.7% bromelain extract, and from about 3% to about 7% dragon’s blood extract by weight percent (%wt/wt).
  • the composition may further comprise one or more additives.
  • the composition comprises about 4.87% babassu oil extract, about 5% arnica oil extract, about 0.5% bromelain extract, and about 5% dragon’s blood extract by weight percent (%wt/wt) and forms a concealer.
  • FIGURE l is a flow diagram illustrating an example embodiment of an exemplary method 100 for making the compositions for use in cosmetic products and personal care products such as masks, serums, and/or concealers.
  • the method comprises combining a desired amount of two or three active ingredients from the group comprising bromelain extract, arnica extract, dragon’s blood extract, and babassu oil extract to form a mixture. Determining the desired amount of each ingredient to be combined may include weighing/measuring the ingredients including the active ingredients comprising babassu oil extract, arnica oil extract, bromelain extract and dragon’s blood extract, and any additives that may optionally be included. In some embodiments, the weighing of ingredients (e g., the active ingredients babassu oil extract, arnica oil extract, bromelain extract, and dragon’s blood extract) provides for a cosmetic composition that is defined by the weight percent (%wt/wt) of its constituents.
  • the composition may optionally comprise one or more additives in addition to the active ingredients.
  • the additives generally consist of biologically inactive ingredients.
  • the biologically active ingredients i.e., pharmacologically active ingredients
  • the babassu oil extract, arnica oil extract, bromelain extract, and dragon’s blood extract - are responsible for providing the composition with biological technical benefits such as anti-aging and repair activity, improved skin protection, strong anti-free radical activity (ORS and NRS), cicatrizing action, anti-inflammatory activity, moisturizing activity, enhanced skin elasticity, and/or epigenetic activity.
  • the active ingredients may be combined in a vessel or a processing tank to form the mixture.
  • the mixture formed is a precursor of the cosmetic composition that comprises the four active ingredients babassu oil extract, arnica oil extract, bromelain extract, and dragon’s blood extract.
  • arnica oil extract, babassu oil extract, and dragon’s blood extract are combined in a vessel to form a mixture that is a precursor of a composition for a facial serum.
  • babassu oil extract and arnica oil extract are combined in a vessel to form a mixture that is a precursor of a composition for a mask.
  • the mixture is mixed to disperse ingredients throughout.
  • the mixture may be mixed until the ingredients are evenly dispersed throughout such that the mixture is substantially uniform.
  • the mixture may be heated to promote dispersion of the ingredients throughout the mixture, but heating is not required.
  • the mixture may be cooled after the ingredients have been dispersed throughout the mixture to mitigate aggregation and settling, but cooling is not required.
  • the mixture may be heated to promote movement and dispersion of ingredients throughout the mixture thereby facilitating mixing of the ingredients.
  • the heating step at 106a is optional and not required.
  • a mixture comprising arnica oil extract, babassu oil extract, and dragon’s blood extract may be heated to a temperature between about 50°C and 55°C and mixed until the mixture is substantially uniform.
  • a mixture comprising arnica oil extract and babassu oil extract may be heated to a temperature between about 75°C and 80°C and mixed until the mixture is substantially uniform. It is to be appreciated that the heating temperature may be dependent on the combination of active ingredients present in the mixture.
  • one or more additives prepared in a separate vessel or processing tank can be combined with the mixture.
  • the mixture may be cooled to slow movement of ingredients throughout the mixture so that the ingredients remain evenly dispersed throughout the mixture.
  • the cooling step at 106b is optional and not required.
  • a mixture comprising arnica oil extract, babassu oil extract, and dragon’s blood extract may be cooled to a temperature between about 35°C and 40°C.
  • a mixture comprising arnica oil extract and babassu oil extract may be cooled to a temperature between about 70°C and 75°C. It is to be appreciated that the cooling temperature may be dependent on the combination of active ingredients included in the mixture.
  • one or more additives prepared in a separate vessel or processing tank may also be combined with the mixture.
  • the remaining one or two active ingredients from the group comprising bromelain extract, arnica extract, dragon’s blood extract, and babassu oil extract are combined with the mixture and mixed to disperse the ingredients throughout, thereby forming a cosmetic composition comprising, by weight percent (%wt/wt), from about 0.1% to about 8% babassu oil extract, from about 1% to about 20% arnica oil extract, from about 0.005% to about 1% bromelain extract, and from about 1% to about 9% dragon’s blood extract.
  • a mixture comprising arnica oil extract, babassu oil extract, and dragon’s blood extract may be combined with bromelain extract and mixed until the resulting composition is substantially uniform.
  • the composition comprises about 1% babassu oil extract, about 15% arnica oil extract, about 0.1% bromelain extract and about 5% dragon’s blood extract by weight percent (%wt/wt), and forms a serum such as, for example, a facial serum.
  • a mixture comprising arnica oil extract and babassu oil extract may be combined with bromelain extract and dragon’s blood extract and mixed until the resulting composition is substantially uniform.
  • a mixture comprising arnica oil extract and babassu oil extract may be combined with bromelain extract, dragon’s blood extract, and additional arnica oil extract and mixed until the resulting composition is substantially uniform.
  • the composition comprises about 1% babassu oil extract, about 6% arnica oil extract, about 0.1% bromelain extract and about 5% dragon’s blood extract by weight percent (%wt/wt), and forms a mask such as, for example, a facial mask.
  • a first aspect of the present disclosure is directed to compositions comprising the active ingredients babassu oil extract, arnica oil extract, bromelain extract, and dragon’s blood extract which are present in active amounts, by weight percent (%wt/wt), wherein the composition is comprised of an anti-inflammatory, anti-edema, anti-erythema complex (AAA Complex) administered to patients/media-spa consumers before or after an aesthetic medical treatment.
  • the AAA Complex is formed from bromelain, croton lechleri (dragon’s blood) or another species in the genus Croton, arnica montana flower extract, and orbignya oleifera seed oil (babassu oil).
  • compositions comprising the active ingredients babassu oil extract, arnica oil extract, bromelain extract, and dragon’s blood extract, wherein the composition comprises the AAA Complex for reducing the visible signs of skin aging.
  • the composition may be administered in a topical composition such as, for example, a lip or facial serum, concealer or mask, or in an orally-administered composition.
  • a topical composition such as, for example, a lip or facial serum, concealer or mask, or in an orally-administered composition.
  • the composition is a topical composition and further comprises a skin-compatible carrier or base.
  • the base may be water based or oil based.
  • a topical or orally-administered composition is applied/ingested and helps to visibly reduce one or more signs of chronological or environmental skin aging (defined below).
  • the exemplary compositions provided herein can be used to reduce one or more of ecchymosis, edema, erythema in a patient undergoing an aesthetic medical treatment comprising the step of administering to the patient a solid, semi-solid, and liquid oral dosage form or gelatine-based chewable.
  • the exemplary compositions provided herein can be used to reduce one or more of ecchymosis, edema, erythema in a patient undergoing an aesthetic medical treatment comprising the step of applying a topical composition to an area on the patient’s skin undergoing the treatment.
  • the oral dosage or topical composition may be administered before and/or after the aesthetic medical treatment.
  • Non-limiting examples of cosmetic ingredients that are suitable for inclusion in topical compositions of the present disclosure include anti oxi dants/ROS scavengers, antiinflammatory agents, skin soothing/healing agents and agents that help visibly reduce the appearance of chronological or environmental signs of skin aging are disclosed in the current editions of the International Cosmetic Ingredient Dictionary and Handbook (published by the Personal Care Products Council, formerly, the Cosmetics Fragrance and Toiletries Association) and Handbook of Pharmaceutical Excipients (published by the American Pharmaceutical Association).
  • Non-limiting examples of antioxidants/ROS scavengers suitable for use in compositions of the present disclosure include: ascorbic acid (vitamin C) and its salts, ascorbyl esters of fatty acids, ascorbic acid derivatives (e.
  • compositions may form topical creams, lotions, ointments, gels, serums, foams, mousse
  • Non-limiting examples of skin soothing and/or healing agents suitable for use in topical compositions of the present disclosure include: allantoin, aloe vera, betulinic acid, bisabolol, dipotassium glycyrrhizinate, oleonolic acid, panthenol and derivatives, pantothenic acid and its derivatives, and ursolic acid.
  • Non-limiting examples of agents that help visibly decrease the appearance of signs of aging include muccopolysaccharides (including hyaluronic acid), aldosamines (including n- acetyl glucosamines) and biologically-active short-chain peptides (e.g., tri-, tetra-, penta-, and hexapeptides, and mixtures thereof).
  • muccopolysaccharides including hyaluronic acid
  • aldosamines including n- acetyl glucosamines
  • biologically-active short-chain peptides e.g., tri-, tetra-, penta-, and hexapeptides, and mixtures thereof.
  • the cosmetic ingredients are botanically-derived (e.g., plant extracts).
  • Non-limiting examples of pharmaceutical ingredients that are suitable for inclusion in topical compositions of the present disclosure are described in the most current versions of the following references, each of which is well-known to the skilled artisan: Burton et aL, Goodman & Gilman ’s: The Pharmacological Basis of Therapeutics., Arndt et al. , Manual of Dermatologic Therapeutics, and Fitzpatrick’s Dermatology in General Medicine .
  • the AAA Complex may also be topically-administered via a transdermal patch.
  • Dermatopharmaceutical ingredients that can be used in combination with the complex of the present disclosure are disclosed in Kerdel, etal., Dermatologic Therapeutics (2005), and in Hardman et al., Goodman & Gilman ’s: The Pharmacological Basis of Therapeutics (10th Edition, 2001), or are known in the relative industry.
  • the AAA Complex may be encapsulated or entrapped in a manner that provides for sustained and/or delayed delivery of the AAA Complex, which includes pH sensitive release (i.e., based on changes in pH) or enzymatic release (enzymes on the surface of the skin, in the oral cavity, or in the gastrointestinal tract).
  • pH sensitive release i.e., based on changes in pH
  • enzymatic release enzymes on the surface of the skin, in the oral cavity, or in the gastrointestinal tract.
  • certain orally-administered products may provide sustained and/or delayed delivery by slow erosion or retention (e.g., in the stomach) or bioadhesion (e.g., to the mucosal lining of the intestinal tract).
  • the dose and dose frequency of topical or orally-applied products comprising the AAA Complex will vary based on, among other factors, the type/severity of the condition being treated.
  • topically-applied products according to the first aspect of the disclosure are applied once or twice daily (e.g., morning and night), but may also be applied one or several times per week, at a dose ranging from about 0. lmg/cm 2 to 2 mg/cm 2
  • Embodiment 1 A composition for treating dermatologic conditions, the composition comprising: from 0.1% to 8% babassu oil extract by weight percent; from 1% to 20% arnica oil extract by weight percent; from 0.005% to 1% bromelain extract by weight percent; and from 1% to 9% dragon’s blood extract by weight percent, wherein the composition provides an anti-inflammatory, anti-edema, anti-erythema complex (AAA Complex).
  • AAA Complex anti-inflammatory, anti-edema, anti-erythema complex
  • Embodiment 2 The composition of Embodiment 1, further comprising: one or more additives.
  • Embodiment 3 The composition of one of Embodiments 1 or 2, wherein the composition forms a facial serum, lip serum, concealer, or mask.
  • Embodiment 4. The composition of any one of Embodiments 1-3, wherein the composition comprises: from 0.5% to 6% babassu oil extract by weight percent; from 5% to 15% arnica oil extract by weight percent; from 0.008% to 0.8% bromelain extract by weight percent; and from 3% to 7% dragon’s blood extract by weight percent.
  • Embodiment 5 The composition of any one of Embodiments 1-4, wherein the composition forms a mask.
  • Embodiment 6 The composition of any one of Embodiments 1 or 3-5, further comprising: one or more additives.
  • Embodiment 7 The composition of any one of Embodiments 1 -6, wherein the composition comprises: from 0.5% to 6% babassu oil extract by weight percent; from 3% to 17% arnica oil extract by weight percent; from 0.05% to 0.6% bromelain extract by weight percent; and from 3% to 7% dragon’s blood extract by weight percent.
  • Embodiment 8 The composition of any one of Embodiments 1-4 or 6-7, wherein the composition forms a serum.
  • Embodiment 9 The composition of any one of Embodiments 1, 3-5, or 7-8, further comprising: one or more additives.
  • Embodiment 10 The composition of any one of Embodiments 1-9, wherein the composition comprises: from 0.5% to 6% babassu oil extract by weight percent; from 3% to 17% arnica oil extract by weight percent; from 0.01% to 0.7% bromelain extract by weight percent; and from 3% to 7% dragon’s blood extract by weight percent.
  • Embodiment 11 The composition of any one of Embodiments 1, 3-5, 7-8, or 10, further comprising: one or more additives.
  • Embodiment 12 The composition of any one of Embodiments 1-4, 6-7, or 9-11, wherein the composition forms a concealer.
  • Embodiment 13 The composition of any one of Embodiments 1-12, wherein the composition is configured to be an orally-administered composition selected from the group of solid, semi-solid, and liquid dosage forms and gelatine-based chewables comprised of the AAA Complex.
  • Embodiment 14 A method of making a composition for treating dermatologic conditions, the method comprising: combining a desired amount of two or three active ingredients selected from the group comprising bromelain extract, arnica extract, dragon’s blood extract, and babassu oil extract to form a first mixture; mixing the first mixture to disperse ingredients throughout the first mixture; combining remaining active ingredients with the first mixture and mixing to form the composition for treating dermatologic conditions, the composition comprising bromelain extract, arnica extract, dragon’s blood extract, and babassu oil extract.
  • Embodiment 15 The method of Embodiment 14, wherein the composition comprises: from 0.1% to 8% babassu oil extract by weight percent; from 1% to 20% arnica oil extract by weight percent; from 0.005% to 1% bromelain extract by weight percent; and from 1% to 9% dragon’s blood extract by weight percent, wherein the composition provides an anti-inflammatory, anti-edema, anti-erythema complex (AAA Complex).
  • AAA Complex anti-inflammatory, anti-edema, anti-erythema complex
  • Embodiment 16 The method of one of Embodiments 14 or 15, wherein the composition forms a facial serum, lip serum, concealer, or mask.
  • Embodiment 17 The method of any one of Embodiments 14-16, wherein the two or three active ingredients selected from the group comprising bromelain extract, arnica extract, dragon’s blood extract, and babassu oil extract are combined in a vessel or a processing tank to form the mixture.
  • Embodiment 18 The method of any one of Embodiments 14-17, further comprising: combining one or more additives with the mixture.
  • Embodiment 19 The method of any one of Embodiments 14-18, further comprising, in the mixing, heating the first mixture to ensure thorough mixing, followed by cooling the first mixture prior to combining the remaining active ingredients.
  • Embodiment 20 The method of any one of Embodiments 14-19, wherein the first mixture is heated to a temperature of from 50°C to 55°C or from 75°C to 80°C, then cooled to a temperature of from 35°C to 40°C or from 70°C to 75°C, respectively, prior to combining the remaining active ingredients.
  • Embodiment 21 A topical composition comprised of
  • an anti-inflammatory, anti-edema, anti-erythema complex consisting essentially of (i) bromelain, (ii) Arnica montana and (iii)) Croton lechleri, or another species in the genus Croton and
  • Embodiment 22 An orally-administered composition selected from the group of solid, semi-solid, and liquid dosage forms and gelatine-based chewables comprised of an antiinflammatory, anti-edema, anti-erythema complex (AAA Complex) consisting essentially of (i) bromelain, (ii) Arnica montana and (iii) Croton lechleri, or another species in the genus Croton.
  • AAA Complex antiinflammatory, anti-edema, anti-erythema complex
  • AAAA Complex consisting essentially of (i) bromelain, (ii) Arnica montana and (iii) Croton lechleri, or another species in the genus Croton.
  • Embodiment 23 A method of reducing one or more of ecchymosis, edema, erythema in a patient undergoing an aesthetic medical treatment comprising the step of applying a topical composition according to Embodiment 21 to an area on the patient’s skin undergoing the treatment.
  • Embodiment 24 The method of Embodiment 23 wherein the topical composition is applied before the aesthetic medical treatment.
  • Embodiment 25 The method of Embodiment 23 wherein the topical composition is applied after the aesthetic medical treatment.
  • Embodiment 26 A method of reducing one or more of ecchymosis, edema, erythema in a patient undergoing an aesthetic medical treatment comprising the step of administering to the patient a solid, semi-solid, and liquid oral dosage form or gelatine-based chewable according to Embodiment 22.
  • Embodiment 27 The method of Embodiment 26 wherein the topical composition is administered before the aesthetic medical treatment.
  • Embodiment 28 The method of Embodiment 26 wherein the topical composition is administered before the aesthetic medical treatment.
  • Embodiment 29 A method of reducing the appearance of visible signs of skin aging selected from the group of (i) fine lines and wrinkles on the face, decollete and/or hands, and (ii) skin redness, comprising the step of administering to a consumer a topical composition according to Embodiment 22.
  • Embodiment 30 A method of reducing the appearance of visible signs of skin aging selected from the group of (i) fine lines and wrinkles on the face, decollete and/or hands, and (ii) skin redness, comprising the step of administering to a consumer a solid, semi-solid, or liquid oral dosage form or gelatine-based chewable according to Embodiment 22.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical & Material Sciences (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne une composition pour le traitement d'affections dermatologiques et son procédé de fabrication. La composition comprend de 0,1 % à 8 % d'extrait d'huile de babassu en pourcentage en poids ; de 1 % à 20 % d'extrait d'huile d'arnica en pourcentage en poids ; de 0,005 % à 1 % d'extrait de bromélaïne en pourcentage en poids ; et de 1 % à 9 % d'extrait de sang de dragon en pourcentage en poids. L'extrait d'huile de babassu, l'extrait d'huile d'arnica, l'extrait de bromélaïne et l'extrait de sang de dragon fournissent un complexe anti-inflammatoire, anti-œdème et anti-érythème (complexe AAA).
PCT/US2024/012704 2023-01-24 2024-01-24 Composition pour le traitement d'affections dermatologiques et son procédé de fabrication Ceased WO2024158867A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363481286P 2023-01-24 2023-01-24
US63/481,286 2023-01-24

Publications (1)

Publication Number Publication Date
WO2024158867A1 true WO2024158867A1 (fr) 2024-08-02

Family

ID=91971162

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/012704 Ceased WO2024158867A1 (fr) 2023-01-24 2024-01-24 Composition pour le traitement d'affections dermatologiques et son procédé de fabrication

Country Status (1)

Country Link
WO (1) WO2024158867A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101787406B1 (ko) * 2017-07-12 2017-10-19 주식회사 한국화장품제조 브로멜라인, 부처브룸, 포도씨, 아르니카 및 레몬밤을 유효성분으로 포함하는 화장료 조성물
US20200384055A1 (en) * 2018-01-02 2020-12-10 Skinkick, Llc Topical Skin Care Compositions
US20210369674A1 (en) * 2016-08-04 2021-12-02 Seattle Gummy Company Health management compositions and methods of making and using thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210369674A1 (en) * 2016-08-04 2021-12-02 Seattle Gummy Company Health management compositions and methods of making and using thereof
KR101787406B1 (ko) * 2017-07-12 2017-10-19 주식회사 한국화장품제조 브로멜라인, 부처브룸, 포도씨, 아르니카 및 레몬밤을 유효성분으로 포함하는 화장료 조성물
US20200384055A1 (en) * 2018-01-02 2020-12-10 Skinkick, Llc Topical Skin Care Compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Dragon's Blood: Anti-Aging Skin Enhancement", LAB GARDENS, 2 June 2020 (2020-06-02), pages 1 - 3, XP093194642, Retrieved from the Internet <URL:https://labgardens.com/blogs/news/dragons-blood-skin-enhancer> *
YILDIRIM YAVUZ SULTAN, GÜLMEZ EMRAH, SAKALLIOĞLU ÖNER, ÇETİNER HASAN, DÜZER SERTAÇ, SUSAMAN NIHAT: "Effect of a Combination of Bromelain and Arnica on Periorbital Edema and Ecchymosis in Septorhinoplasty", KULAK BURUN BOĞAZ VE BAŞ BOYUN CERRAHISI DERGISI, vol. 32, no. 1, 26 January 2024 (2024-01-26), pages 37 - 44, XP093194640, ISSN: 1300-6525, DOI: 10.24179/kbbbbc.2023-99648 *

Similar Documents

Publication Publication Date Title
KR102165289B1 (ko) 식물 추출물을 포함하는 국소 스킨 케어 제형
KR101779999B1 (ko) 국소 피부 케어 제형
CN102711721B (zh) 皮肤护理制剂
KR101480700B1 (ko) 복방 생약 추출물을 유효성분으로 함유하는 피부 외용제조성물
CN106074278B (zh) 包含植物提取物的局部护肤制剂
KR101910482B1 (ko) 자보티카바 및 캐슈 과육 및 이들의 추출물을 포함하는 국소 피부 케어 제형
MXPA04000002A (es) Agente con un contenido de gasa (aceite), que contiene un extracto de cebolla su preparacion y su utilizacion para el cuidado, la prevencion o el tratamiento de un tejido cutaneo danado, en particular de cicatrices.
CN109125107B (zh) 一种有效改善和修复面部激素依赖性皮炎的多肽组合物
EP2763686A1 (fr) Composition pour le traitement de lésions de la peau
WO2014002232A1 (fr) Inhibiteur de décomposition d&#39;acide hyaluronique comprenant de l&#39;extrait de romarin et de l&#39;acétate de rétinol
US12396965B2 (en) Putrescine topical barrier formulation
WO2024158867A1 (fr) Composition pour le traitement d&#39;affections dermatologiques et son procédé de fabrication
CN115154360A (zh) 一种具有美白祛斑及保湿功效的组合物及其应用
EP4085913A1 (fr) Composition comprenant du nicotinamide, zinc, cuivre et glutathion pour le traitement de la rosacée
KR20230143023A (ko) 시지지움 포르모슘 추출물을 유효성분으로 포함하는 피부 개선용 조성물
CN114869998A (zh) 一种修复皮肤屏障的组合物及其制备和应用
KR20240166050A (ko) 초미립자 진주 및 저분자 콜라겐을 포함하는 피부 탄력 개선용 조성물
EA043462B1 (ru) Омолаживающая сыворотка на основе гиалуроновой кислоты и коллагена (2 варианта)
KR20100135160A (ko) 항염증용 조성물
Kvalheim et al. SKIN CARE PRODUCTS AND THEIR EFFECT ON AGING SKIN
RO129526A2 (ro) Cremă destinată eliminării vitiligo
HK1201047A1 (en) Skin care formulation
HK1192156B (en) Topical skin care formulations comprising jaboticaba and cashew fruit pulps and extracts thereof
BG66832B1 (bg) Състав на биологично активни смеси от слуз на охлюви helix aspersa, за влагане в хранителни добавки и козметичната промишленост
WO2007064966A2 (fr) Compositions pharmaceutiques et dermatocosmétiques comprenant un extrait de durio zibethinus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24747720

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE